AI Article Synopsis
- Researchers are looking for better ways to diagnose multiple sclerosis (MS) because it's tough to identify it correctly.
- This study compared MRI scans from patients with Fabry disease and those with relapsing-remitting MS to see how common a sign called the central vein sign (CVS) is.
- The results showed that CVS is found in a lot of MS patients, especially those who are newly diagnosed, but it wasn't seen at all in Fabry disease patients, which suggests it could help diagnose MS better.
Article Abstract
Objectives: Although the use of specific MRI criteria has significantly increased the diagnostic accuracy of multiple sclerosis (MS), reaching a correct neuroradiological diagnosis remains a challenging task, and therefore the search for new imaging biomarkers is crucial. This study aims to evaluate the incidence of one of the emerging neuroradiological signs highly suggestive of MS, the central vein sign (CVS), using data from Fabry disease (FD) patients as an index of microvascular disorder that could mimic MS.
Methods: In this retrospective study, after the application of inclusion and exclusion criteria, MRI scans of 36 FD patients and 73 relapsing-remitting (RR) MS patients were evaluated. Among the RRMS participants, 32 subjects with a disease duration inferior to 5 years (early MS) were also analyzed. For all subjects, a Fazekas score (FS) was recorded, excluding patients with FS = 0. Different neuroradiological signs, including CVS, were evaluated on FLAIR T2-weighted and spoiled gradient recalled echo sequences.
Results: Among all the recorded neuroradiological signs, the most striking difference was found for the CVS, with a detectable prevalence of 78.1% (57/73) in RRMS and of 71.4% (25/32) in early MS patients, while this sign was absent in FD (0/36).
Conclusions: Our results confirm the high incidence of CVS in MS, also in the early phases of the disease, while it seems to be absent in conditions with a different etiology. These results corroborate the possible role of CVS as a useful neuroradiological sign highly suggestive of MS.
Key Points: • The search for new imaging biomarkers is crucial to achieve a correct neuroradiological diagnosis of MS. • The CVS shows an incidence superior to 70% in MS patients, even in the early phases of the disease, while it appears to be absent in FD. • These findings further corroborate the possible future central role of CVS in distinguishing between MS and its mimickers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00330-021-08487-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Phase four of the Alzheimer's Disease Neuroimaging Initiative (ADNI4) began in 2023. This time-period corresponded to MRI vendors introducing product sequences with compressed sensing (CS), cross-vendor adoption of arterial spin-labelling (ASL) and multi-band slice excitation, and hardware improvements (head-coils, increased gradient amplitudes). These advances enabled the acquisition of new imaging measures and reduced scan times.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Background: With an aging population, it is essential to identify subtle features of brain pathology - both neurodegenerative and vascular - at an early stage, which may predict risk of future decline. We used diffusion MRI (dMRI) to assess grey matter cortical microstructure and investigate associations with 1) Alzheimer's disease (AD) pathology and 2) mid/late-life vascular risk (as measured by blood pressure (BP)).
Method: 151 asymptomatic individuals from the British 1946 birth cohort underwent combined PET/MR with [18F]florbetapir Aβ-PET at ∼73yrs, and [18F]MK-6240 tau-PET at ∼76yrs.
Biomarkers.
Alzheimers Dement
December 2024
Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.
Background: Understanding when Aβ positive cognitively normal individuals develop tau pathology has important implications for treatment with anti-Aβ therapies. We employed a changepoint regression approach to estimate time from Aβ-PET positivity to regionally elevated tau-PET in a population-based cohort of primarily cognitively unimpaired individuals.
Method: Participants from Insight 46 (1946 British birth cohort) underwent two [F]florbetapir Aβ-PET scans and a sub-sample enriched for Aβ were also scanned with [F]MK-6240 tau-PET, characteristics are presented in Table 1.
Background: Phase four of the Alzheimer's Disease Neuroimaging Initiative (ADNI4) began in 2023. This time-period corresponded to MRI vendors introducing product sequences with compressed sensing (CS), cross-vendor adoption of arterial spin-labelling (ASL) and multi-band slice excitation, and hardware improvements (head-coils, increased gradient amplitudes). These advances enabled the acquisition of new imaging measures and reduced scan times.
View Article and Find Full Text PDFAlzheimer's Imaging Consortium.
Alzheimers Dement
December 2024
Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.
Background: Understanding when Aß positive cognitively normal individuals develop tau pathology has important implications for treatment with anti-Aß therapies. We employed a changepoint regression approach to estimate time from Aß-PET positivity to regionally elevated tau-PET in a population-based cohort of primarily cognitively unimpaired individuals.
Method: Participants from Insight 46 (1946 British birth cohort) underwent two [18F]florbetapir Aß-PET scans and a sub-sample enriched for Aß were also scanned with [18F]MK-6240 tau-PET, characteristics are presented in Table 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!